The meta- analysis showed a significant increase in plasma adiponectin levels following statin therapy .
Although statins are known to increase the risk for new onset diabetes mellitus , our data might suggest that the mechanism for this is unlikely to be due to a reduction in adiponectin expression
BACKGROUND AND AIMS The effect of statin therapy on plasma adiponectin levels has not been conclusively studied .
Therefore , we aim ed to evaluate this effect through a systematic review and meta- analysis of available r and omized controlled trials ( RCTs ) .
Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.
OBJECTIVE Diabetes , a major health problem worldwide , increases the risk of cardiovascular disease and its associated mortality : The Long-Term Intervention with Pravastatin in Ischemic Disease ( LIPID ) trial showed that cholesterol-lowering treatment with pravastatin reduced mortality and coronary heart disease ( CHD ) events in 9014 patients aged 31 - 75 years with CHD and total cholesterol 4.0 - 7.0 mmol/l . We measured the effects of pravastatin therapy , 40 mg/day over 6.0 years , on the risk of CHD death or nonfatal myocardial infa rct ion and other cardiovascular outcomes in 1,077 LIPID patients with diabetes and 940 patients with impaired fasting glucose ( IFG ) . RESULTS In patients allocated to placebo , the risk of a major CHD event was 61 % higher in patients with diabetes and 23 % higher in the IFG group than in patients with normal fasting glucose , and the risk of any cardiovascular event was 37 % higher in the diabetic group and 19 % higher in the IFG group . Pravastatin therapy reduced the risk of a major CHD event overall from 15.9 to 12.3 % ( relative risk reduction [ RRR ] 24 % , P < 0.001 ) and from 23.4 to 19.6 % in the diabetic group ( 19 % , P = 0.11 ) ; in the diabetic group , the reduction was not significantly different from the reductions in the other groups . Pravastatin reduced the risk of any cardiovascular event from 52.7 to 45.2 % ( 21 % , P < 0.008 ) in patients with diabetes and from 45.7 to 37.1 % ( 26 % , P = 0.003 ) in the IFG group . Pravastatin reduced the risk of stroke from 9.9 to 6.3 % in the diabetic group ( RRR 39 % , CI 7 - 61 % , P = 0.02 ) and from 5.4 to 3.4 % in the IFG group ( RRR 42 % , CI -9 to 69 % , P = 0.09 ) . Pravastatin did not reduce the incidence of diabetes . Over 6 years , pravastatin therapy prevented one major CHD event ( CHD death or nonfatal myocardial infa rct ion ) in 23 patients with IFG and 18 patients with diabetes . A meta- analysis of other major trials confirmed the high absolute risks of diabetes and IFG and the absolute benefits of statin therapy in these patients . CONCLUSIONS Cholesterol-lowering treatment with pravastatin therapy prevents cardiovascular events , including stroke , in patients with diabetes or IFG and established CHD
The meta- analysis showed a significant increase in plasma adiponectin levels following statin therapy .
Although statins are known to increase the risk for new onset diabetes mellitus , our data might suggest that the mechanism for this is unlikely to be due to a reduction in adiponectin expression
BACKGROUND AND AIMS The effect of statin therapy on plasma adiponectin levels has not been conclusively studied .
Therefore , we aim ed to evaluate this effect through a systematic review and meta- analysis of available r and omized controlled trials ( RCTs ) .